During the first cycle of the grant we explored the mechanisms underlying the anti-atherogenic effects of apolipoprotein E (apoE) expressed by macrophages, and delineated a unique hepatic axis between LDL receptor (LDLR) related protein (LRP) and apoE. Because both LRP and apoE are abundantly expressed in the macrophage, we postulate that this axis is operational in the vessel wall as well, where it may direct the uptake of intimal lipoproteins to a specific intracellular routing.
Specific aim 1 will address the role of macrophage LRP in atherogenesis. The hypothesis tested is that LRP is the mediator of the anti-atherogenic effects of apoE in the artery wall, and that its deletion will promote lesion growth. Because apoE is a physiologic driver of cholesterol efflux from cells, its anti-atherogenic effects may be mediated by a more complex regulation of cholesterol homeostasis involving both uptake and disposition of macrophage cholesterol.
Specific aim 2 will address the effects of apoE receptor binding defective variants expressed by the macrophage on cholesterol efflux and lipoprotein uptake, as well as their interaction with macrophage LRP. The hypothesis tested is that apoE affects cholesterol efflux in vivo not only by acting as an accepter but also by simulating LRP-mediated lipoprotein uptake. Multiple pathways to cholesterol efflux are present in macrophages, and the ATP-binding cassette (ABC) transporters and the scavenger receptor type B1 (SR-B1) can act as channels that deliver cellular cholesterol to extracellular acceptors. ABCA1 transposes phospholipids and cholesterol to apoAI. SR-B1 is normally involved in hepatic HDL cholesterol uptake, but in the macrophage cholesterol can also flow in the opposite direction and result in net efflux.
Specific aim 3 will study the mechanism of apoE-mediated cholesterol efflux from macrophages and its relationship, if any, with either ABCA1 or SR-B1. The hypothesis tested is that apoE-mediated cholesterol efflux from macrophages is independent from ABCA1 or SR-B1 mechanisms.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
2R01HL057986-06
Application #
6579271
Study Section
Metabolism Study Section (MET)
Program Officer
Applebaum-Bowden, Deborah
Project Start
1998-01-01
Project End
2007-12-31
Budget Start
2003-01-01
Budget End
2003-12-31
Support Year
6
Fiscal Year
2003
Total Cost
$377,500
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Kaseda, Ryohei; Tsuchida, Yohei; Yang, Hai-Chun et al. (2018) Chronic kidney disease alters lipid trafficking and inflammatory responses in macrophages: effects of liver X receptor agonism. BMC Nephrol 19:17
Fazio, Sergio; Pamir, Nathalie (2016) HDL Particle Size and Functional Heterogeneity. Circ Res 119:704-7
Zhu, Lin; Giunzioni, Ilaria; Tavori, Hagai et al. (2016) Loss of Macrophage Low-Density Lipoprotein Receptor-Related Protein 1 Confers Resistance to the Antiatherogenic Effects of Tumor Necrosis Factor-? Inhibition. Arterioscler Thromb Vasc Biol 36:1483-95
Giunzioni, Ilaria; Tavori, Hagai; Covarrubias, Roman et al. (2016) Local effects of human PCSK9 on the atherosclerotic lesion. J Pathol 238:52-62
Shapiro, Michael D; Fazio, Sergio (2016) From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk. Circ Res 118:732-49
Bartlett, Jacquelaine; Predazzi, Irene M; Williams, Scott M et al. (2016) Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor? New Insights From the Framingham Offspring Study. Circ Cardiovasc Qual Outcomes 9:206-212
Jahangir, Eiman; Lipworth, Loren; Edwards, Todd L et al. (2015) Smoking, sex, risk factors and abdominal aortic aneurysms: a prospective study of 18?782 persons aged above 65 years in the Southern Community Cohort Study. J Epidemiol Community Health 69:481-8
Tavori, Hagai; Su, Yan Ru; Yancey, Patricia G et al. (2015) Macrophage apoAI protects against dyslipidemia-induced dermatitis and atherosclerosis without affecting HDL. J Lipid Res 56:635-43
Kaseda, Ryohei; Jabs, Kathy; Hunley, Tracy E et al. (2015) Dysfunctional high-density lipoproteins in children with chronic kidney disease. Metabolism 64:263-73
Yamamoto, Suguru; Zhong, Jiayong; Yancey, Patricia G et al. (2015) Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype. Atherosclerosis 242:56-64

Showing the most recent 10 out of 96 publications